CVM — CEL-SCI Corp
AMEX · Healthcare · Biotechnology
$1.65
+$0.04 (+2.50%)
CEL-SCI Corp (CVM) is a biotechnology company listed on AMEX. It is led by Geert R. Kersten Esq., based in 8229 Boone Boulevard, Vienna, VA, United States, 22182. CEL-SCI Corporation, a clinical-stage biotechnology company, engages in the research and development to treat cancer and other diseases by using the immune system in the United States. The company's lead immunotherapy is Multikine, which has completed Phase III clinical trials for the potential treatment of certain head and neck cancers. It is also developing Ligand Epitope Antigen Presentation System (LEAPS) technology, a patented T-cell modulation process that stimulates the human immune system to fight bacterial, viral, parasitic infections, autoimmune conditions, allergies, transplantation rejections, and cancer, as well as to potentially treat rheumatoid arthritis. In addition, the company's LEAP product candidates include CEL-2000; CEL-4000; and CEL-5000 that are in preclinical trials for potential rheumatoid arthritis therapeutic treatments. CEL-SCI Corporation has a strategic partnership with Saudi Arabian Pharma Company for Multikine in the treatment of head and neck cancer. The company was incorporated in 1983 and is headquartered in Vienna, Virginia.
Net income was -$19.3M. CVM currently screens at market cap $22.3M.
Use this CVM page for company research — sector, financials, and the latest filing takeaway — not a live tape. The session quote (last, range, volume) lives on the CVM quote page. Cached 10-K, 10-Q, 8-K, and Form 4 exhibits are on the CVM SEC filings page. Lician reads the product cache first so this HTML stays unique to CEL-SCI Corp even when a live quote feed is slow.
About CEL-SCI Corp
CEL-SCI Corporation, a clinical-stage biotechnology company, engages in the research and development to treat cancer and other diseases by using the immune system in the United States. The company's lead immunotherapy is Multikine, which has completed Phase III clinical trials for the potential treatment of certain head and neck cancers. It is also developing Ligand Epitope Antigen Presentation System (LEAPS) technology, a patented T-cell modulation process that stimulates the human immune system to fight bacterial, viral, parasitic infections, autoimmune conditions, allergies, transplantation rejections, and cancer, as well as to potentially treat rheumatoid arthritis. In addition, the company's LEAP product candidates include CEL-2000; CEL-4000; and CEL-5000 that are in preclinical trials for potential rheumatoid arthritis therapeutic treatments. CEL-SCI Corporation has a strategic partnership with Saudi Arabian Pharma Company for Multikine in the treatment of head and neck cancer. The company was incorporated in 1983 and is headquartered in Vienna, Virginia.
CVM Key Statistics
Market Cap
$22.32M
Volume
169,258
Previous Close
$1.60
Day Range
$1.52 – $1.61
EPS
-$0.51
Revenue
$0.00
Net Income
-$26.92M
Gross Profit
$0.00
Free Cash Flow
$0.00
CVM Financials
Annual income statement in USD. Latest reported periods first.
| Line | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 |
| Cost of Revenue | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross Profit | $0.00 | $0.00 | $0.00 | $0.00 |
| Operating Income | $0.00 | $0.00 | $0.00 | $0.00 |
| Net Income | -$26.92M | -$32.19M | -$36.70M | $36.36M |
| EPS (Diluted) | -$0.51 | -$0.73 | -$0.87 | -$0.90 |
Total Assets
$26.99M
Total Debt
$0.00
Shareholders' Equity
$0.00
Cash & Equivalents
$0.00
Operating Cash Flow
-$18.81M
Free Cash Flow
$0.00
CEL-SCI Corp Company Information
- Chief Executive & Financial Officer, CAO,Treasurer and Director
- Geert R. Kersten Esq.
- Headquarters
- 8229 Boone Boulevard, Vienna, VA, United States, 22182
- Website
- cel-sci.com
- Phone
- 703 506 9460
- IPO / Founded
- 1987-01-01
- Sector
- Healthcare
- Industry
- Biotechnology